What is a ‘liquid biopsy’ and how does it monitor colorectal cancer?
Kristin Alfaro2023-03-28T22:07:02+00:00https://www.youtube.com/watch?v=SYrsSV36-uk
Enterome CLAUDE study announcement
Kristin Alfaro2024-04-28T17:47:27+00:00Dr. Arvind Dasari reviews how the current study will evaluate the microbiome-derived therapeutic vaccine EO2040 in combination with nivolumab in patients with circulating tumor DNA-defined Minimal Residual Disease (MRD) of colorectal cancer stage II, III, or IV after completion of standard curative therapy. https://youtu.be/Fzu48PE5V_Q
Survival in metastatic colorectal cancer has improved, but further drug development needed
Kristin Alfaro2023-03-24T16:17:47+00:00Survival for patients with metastatic colorectal cancer has improved steadily since 2012, according to retrospective study results. Researchers attributed this trend to several factors, including use of immunotherapy, surgical resection of liver metastases and use of third-line chemotherapy. The analysis included 1,420 patients with de novo metastatic colorectal cancer who received their primary treatment at The University of MD Anderson Cancer Center from 2004 through 2019. Despite survival improvements, results showed the majority of patients died within 5 years of diagnosis. This highlights the need for more study and the development of more effective therapeutic strategies, particularly targeted treatments, researchers concluded. Healio [...]
Dr. Morris on the Investigation of the Role of ctDNA in Stage II CRC
Kristin Alfaro2023-01-31T19:09:55+00:00Van K. Morris, MD, discusses the evaluation of circulating tumor as a predictive biomarker for the use of adjuvant chemotherapy in patients with low-risk, stage II colon cancer. https://www.onclive.com/view/dr-morris-on-the-investigation-of-the-role-of-ctdna-in-stage-ii-crc
Dr. Arvind Dasari – Results from the DYNAMIC Study
Kristin Alfaro2023-01-25T03:45:08+00:00Dr. Arvind Dasari reviews the reported results of the DYNAMIC study, in which a circulating tumor DNA (ctDNA)-guided approach reduced the use of adjuvant chemotherapy without compromising recurrence-free survival in patients with stage II colon cancer.
Dr. Alisha Bent – The DAILY Study
Kristin Alfaro2023-01-24T22:25:41+00:00Dr. Alisha Bent, Assistant Professor of Gastrointestinal Medical Oncology at University of Texas MD Anderson Cancer Center introduces a clinical trial, The Daily Study. This study aims to uncover the impact of intensive lifestyle interventions in the setting of colorectal cancers and with the use of ctDNA surveillance. ClinicalTrials.gov Identifier: NCT05036109 Dr. Alisha Bent, Assistant Professor of Gastrointestinal Medical Oncology at University of Texas MD Anderson Cancer Center introduces The Daily Study, an intensive lifestyle intervention study.